Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma

We are extremely pleased that patients in Europe with multiple myeloma will now, like patients in the U.S., have the opportunity for treatment with the subcutaneous formulation of daratumumab.